company background image

NUTEX Investments BUSE:NUTEX Stock Report

Last Price


Market Cap







07 Aug, 2022


Company Financials
NUTEX fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

NUTEX Stock Overview

NUTEX Investments Public Limited Company provides health conserving, health improving, dietary supplement, and cosmetic products in Hungary and internationally.

NUTEX Investments Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NUTEX Investments
Historical stock prices
Current Share PriceFt9.46
52 Week HighFt22.85
52 Week LowFt8.60
1 Month Change0.21%
3 Month Change-15.91%
1 Year Change-56.10%
3 Year Change-67.93%
5 Year Change-87.55%
Change since IPO-99.96%

Recent News & Updates

Shareholder Returns

NUTEXHU PharmaceuticalsHU Market

Return vs Industry: NUTEX underperformed the Hungarian Pharmaceuticals industry which returned 4.4% over the past year.

Return vs Market: NUTEX underperformed the Hungarian Market which returned -22.9% over the past year.

Price Volatility

Is NUTEX's price volatile compared to industry and market?
NUTEX volatility
NUTEX Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in HU Market8.4%
10% least volatile stocks in HU Market3.0%

Stable Share Price: NUTEX is more volatile than 75% of Hungarian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: NUTEX's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Hungarian stocks.

About the Company

n/an/aGábor Csereklei

NUTEX Investments Public Limited Company provides health conserving, health improving, dietary supplement, and cosmetic products in Hungary and internationally. The company was formerly known as HUMET Trade, Research and Development Public Limited Company and changed its name to NUTEX Investments Public Limited Company in February 2011. NUTEX Investments Public Limited Company is based in Budapest, Hungary.

NUTEX Investments Fundamentals Summary

How do NUTEX Investments's earnings and revenue compare to its market cap?
NUTEX fundamental statistics
Market CapFt1.40b
Earnings (TTM)-Ft32.42m
Revenue (TTM)Ft450.00k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NUTEX income statement (TTM)
Cost of RevenueFt0
Gross ProfitFt450.00k
Other ExpensesFt32.87m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date


Earnings per share (EPS)-0.22
Gross Margin100.00%
Net Profit Margin-7,204.67%
Debt/Equity Ratio0.0%

How did NUTEX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is NUTEX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUTEX?

Other financial metrics that can be useful for relative valuation.

NUTEX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does NUTEX's PB Ratio compare to its peers?

NUTEX PB Ratio vs Peers
The above table shows the PB ratio for NUTEX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2x
575 Endurance RP
ROSE Instituto Rosenbusch
524314 Gujarat Terce Laboratories
524632 Shukra Pharmaceuticals
NUTEX NUTEX Investments

Price-To-Book vs Peers: NUTEX is good value based on its Price-To-Book Ratio (0.3x) compared to the peer average (2x).

Price to Earnings Ratio vs Industry

How does NUTEX's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Book vs Industry: NUTEX is good value based on its Price-To-Book Ratio (0.3x) compared to the European Pharmaceuticals industry average (2.2x)

Price to Book Ratio vs Fair Ratio

What is NUTEX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUTEX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NUTEX's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of NUTEX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NUTEX (HUF9.46) is trading below our estimate of fair value (HUF57.65)

Significantly Below Fair Value: NUTEX is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is NUTEX Investments forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NUTEX Investments has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine whether NUTEX Investments is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • NUTEX Investments competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has NUTEX Investments performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Last years earnings growth

Earnings and Revenue History

Quality Earnings: NUTEX is currently unprofitable.

Growing Profit Margin: NUTEX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if NUTEX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare NUTEX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUTEX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.3%).

Return on Equity

High ROE: NUTEX has a negative Return on Equity (-0.7%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is NUTEX Investments's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NUTEX's short term assets (HUF3.8B) exceed its short term liabilities (HUF2.4M).

Long Term Liabilities: NUTEX has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: NUTEX is debt free.

Reducing Debt: NUTEX has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if NUTEX has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if NUTEX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is NUTEX Investments's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NUTEX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NUTEX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NUTEX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NUTEX's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: NUTEX is not paying a notable dividend for the Hungarian market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NUTEX has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Gábor Csereklei

no data


Gábor Csereklei serves as Chief Executive Officer for Investor Relations at NUTEX Investments Public Limited Company.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.5%.

Top Shareholders

Company Information

NUTEX Investments Public Limited Company's employee growth, exchange listings and data sources

Key Information

  • Name: NUTEX Investments Public Limited Company
  • Ticker: NUTEX
  • Exchange: BUSE
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: Ft1.401b
  • Shares outstanding: 148.11m
  • Website:


  • NUTEX Investments Public Limited Company
  • Telepes u. 53
  • Budapest
  • 1147
  • Hungary


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/07 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.